Veröffentlichung Nr.3
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, […]
Veröffentlichung Nr.2
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, […]
Transkript.de
Transkript.de reports about the new partnership of CELLphenomics and KYAN Therapeutics. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry.
Pressemitteilung Nr.3
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, […]
Pressemitteilung Nr.2
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, […]
Pressemitteilung Nr.1
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, […]
Christian Regenbrecht
Dr. Christian Regenbrecht is co-founder and CEO of CELLphenomics.Prior to founding CELLphenomics, Christian was principal investigator at the Institute of Pathology, Charité – Universitätsmedizin Berlin and was responsible for the establishment of complex cell culture models in several publicly funded projects, including IMI’s Oncotrack and BMBF’s TREAT20. In this role, Christian acquired external funding from […]
Quirin Graf Adelmann
Quirin Graf Adelmann was born near Munich and grew up bilingually in France and Germany. After studying law at Humboldt University in Berlin, he worked as an employed managing director in the automotive and real estate sectors before becoming an independent entrepreneur in 2010.Quirin is active in the fields of culture, health, FinTech, GovTech, BioTech, […]
Christoph Reinhard
Dr. Christoph Reinhard has spend his whole career in oncology drug development in biotechnology and pharma companies with a special focus on target identification and translational research. Special emphasis lies on technologies to identify and utilize biomarkers for drug efficacy and tumor prognosis. Christoph strived to complement the company specific research with engagement in large […]
Lena Wedeken
Dr. Lena Wedeken studied human biology at the Philipps-University Marburg, Germany and obtained her PhD in molecular biology/biochemistry from the Westfälische Wilhelms-University Münster, Germany in 2011. During her postdoctoral fellowship in stem cell biology at the Beckman Research Institute of City of Hope in Duarte, CA, USA, she became an expert in the derivation and […]
